FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 
EBMT Center Identification Code (CIC):    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type: (check all that apply) 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product Type: (check all that apply) 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

  
gfedcb

If this is a report of a second or subsequent transplant, check here and continue with question 42.

  
 
1  What was the date of onset for the first Multiple Sclerosis (MS) symptom(s)? __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date unknown

  
 
2  What was the date of diagnosis of MS? __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date unknown

 
 

3  Are any of the recipient's family members also affected with MS?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

4  Monozygotic twin

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

5  Dizygotic twin

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

6  Other first degree relative (sibling, parent, child)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

7  Second degree relative (grandparent, aunt, uncle, first cousin)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

8  Other 
relative

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
9  Specify 

relationship:
   

 
 

10  Was the diagnosis of MS corroborated by laboratory or radiological test results?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Key Fields 

  Disease Assessment at Diagnosis Questions: 1 - 13

Form 2043 R3.0: Multiple Sclerosis Pre-HSCT data  
Center:  CRID: 

                CIBMTR Form 2043 revision 3.0 last updated July 2011
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 6



 
 

11  CSF oligoclonal bands present

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

12  Elevated IgG index

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

13  MRI brain lesions consistent with MS

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
14  Did the recipient receive any disease-modifying treatments between the time of diagnosis and prior to mobilization for stem cell collection (or prior to the preparative regimen if 

mobilization was not done)? 

    
 nmlkji

yes  
 nmlkji

no  

 
 
15  Specify the date the first disease-modifying therapy started: __ __ __ __ - __ __- __ __  

 
 

16  Alemtuzumab (Campath)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

17  Azathioprine (Azasan, Imuran)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

18  Belimumab (LymphoStat-B)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

19  Cladribine (2-CdA, Leustatin)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

20  Corticosteriods (chronic use, not to treat acute relapse)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

21  Cyclophosphamide (CTX, Cytoxan, Neosar)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

22  Daclizumab (Zenapax, anti-CD25)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

23  Fingolimod (FTY720)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

24  Fumarate (oral) (BG00012)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

25  Glatiramer acetate (Copaxone) [previously copolymer-1]

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

26  Immune globulin (IVIG, Gamimune, Gammagard)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

27  Interferon beta-1a (Avonex, Rebif)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

28  Interferon beta-1b (Betaseron)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

29  Laquinimod

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Pre-HSCT Treatment for Multiple Sclerosis Questions: 14 - 41

Form 2043 R3.0: Multiple Sclerosis Pre-HSCT data  
Center:  CRID: 

                CIBMTR Form 2043 revision 3.0 last updated July 2011
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 6



 
 

30  Methotrexate (MTX, Folex)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

31  Mitoxantrone (Novantrone)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

32  Natalizumab (Tysabri, Antegren)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

33  Mycophenolate mofetil (MMF, Cellcept)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

34  Rituximab (anti-CD20, Rituxan, MabThera)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

35  Sirolimus (Rapamune)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

36  Tacrolimus (FK 506, Prograf)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

37  Teriflunomide (oral) (HMR1726)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

38  Blinded randomized trial agent

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
39  Specify trial agent:    

 
 

40  Other treatment

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
41  Specify other treatment:    

 
 
42  Date of baseline evaluation: __ __ __ __ - __ __- __ __  

  
 
43  Specify the number of relapses of MS during the 1-year period prior to the baseline assessment:    

 
  

gfedcb
number unknown

 
 

44  Specify the disease course during the 2-year period prior to the baseline assessment:

    
 nmlkji

relapsing remitting  

 nmlkji
secondary progressive  

 nmlkji
primary progressive  

 nmlkji
progressive relapsing  

 nmlkji
Unknown  

 
 

45  Was the Kurtzke Expanded Disability Status Scale (EDSS) assessed by a neurologist during the 2-year period prior to the baseline assessment?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
46  Date of EDSS assessment: __ __ __ __ - __ __- __ __  

 
 
47  EDSS:    

 
 

48  Were the Kurtzke Functional Systems Scores (FSS) assessed by a neurologist during the baseline assessment?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Baseline Assessment for MS Performed at the Transplant Center Questions: 42 - 65

  EDSS assessment(s) (1) Questions: 46 - 47 

Form 2043 R3.0: Multiple Sclerosis Pre-HSCT data  
Center:  CRID: 

                CIBMTR Form 2043 revision 3.0 last updated July 2011
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 6



  
 
49  Pyramidal    

 
  

gfedcb
score unknown

  
 
50  Cerebellar    

 
  

gfedcb
score unknown

  
 
51  Brainstem    

 
  

gfedcb
score unknown

  
 
52  Sensory    

 
  

gfedcb
score unknown

  
 
53  Bowel and bladder    

 
  

gfedcb
score unknown

  
 
54  Visual    

 
  

gfedcb
score unknown

  
 
55  Cerebral:    

 
  

gfedcb
score unknown

  
 
56  Other function:    

 
  

gfedcb
score unknown

 
 
57  Specify other function:    

  
 
58  Specify the EDSS at baseline assessment:    

 
  

gfedcb
EDSS unknown

 
 

59  Was a MRI scan of the brain conducted during the baseline assessment?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  
 
60  Date of baseline MRI: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date unknown

 
 

61  Are T2 lesions present on the MRI?

    
 nmlkji

yes  
 nmlkji

no  

  
 
62  Specify number of T2 lesions:    

 
  

gfedcb
number unknown

 
 

63  Was gadolinium contrast used for this assesment?

    
 nmlkji

yes  
 nmlkji

no  

 
 

64  Are gadolinium-enhancing lesions present on the MRI?

    
 nmlkji

yes  
 nmlkji

no  

  
 
65  Specify number of lesions:    

 
  

gfedcb
number unknown

 

  

gfedcb
This section records pre-mobilization information for autologous HSCTs only; if this report is for an allogeneic HSCT, or if the autologous HSCT did not use mobilization, check here 
and continue with question 71. 

 
 

66  Did the recipient receive treatment, prior to any stem cell harvest, to enhance the autologous product collection for this HSCT?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify treatment(s): 
 

67  Cyclophosphamide

    
 nmlkji

yes  
 nmlkji

no  

 
 

68  Growth factors

    
 nmlkji

yes  
 nmlkji

no  

 
 

69  Other mobilization chemotherapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
70  Specify other chemotherapy:    

 

  

gfedcb
Information for this section should come from the most recent evaluation performed <= 2 weeks prior to the preparative regimen. If the recipient was not evaluated prior to the 
preparative regimen, check here. 

  For recipients of autologous cells who underwent mobilization for stem cell collection, a second disease assessment is required prior to the preparative regimen.  

 
 
71  Date of evaluation prior to the preparative regimen: __ __ __ __ - __ __- __ __  

 
 
72  Specify the number of relapses of MS that occurred after the start of mobilization and the start of the preparative regimen:    

 
  

gfedcb
number unknown

  Stem Cell Mobilization for Autologous HSCT Questions: 66 - 70

  Most Recent Disease Assessment Prior to the Start of the Preparative (Conditioning) Regimen Questions: 71 - 95

Form 2043 R3.0: Multiple Sclerosis Pre-HSCT data  
Center:  CRID: 

                CIBMTR Form 2043 revision 3.0 last updated July 2011
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 6



 
 

73  Did the recipient experience worsening disability or continuous progression of MS between mobilization and the start of the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

74  Was a MRI scan of the brain conducted prior to the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
75  Date of most recent MRI performed prior to the preparative regimen: __ __ __ __ - __ __- __ __  

 
 

76  Does the radiology report include a comparison with the baseline MRI?

    
 nmlkji

yes  
 nmlkji

no  

 
 

77  Are T2 lesions present on the MRI?

    
 nmlkji

yes  
 nmlkji

no  

  
 
78  Specify the number of T2 lesions:    

 
  

gfedcb
number unknown

 
 

79  Was gadolinium contrast used for this assessment?

    
 nmlkji

yes  
 nmlkji

no  

 
 

80  Are gadolinium-enhancing lesions present on the MRI?

    
 nmlkji

yes  
 nmlkji

no  

  
 
81  Specify the number of gadolinium-enhancing lesions:    

 
  

gfedcb
number unknown

 
 

82  In comparision to the baseline MRI, does the radiology report state evidence of new or enlarged T2 lesions?

    
 nmlkji

yes  
 nmlkji

no  

 
 

83  In comparision to the baseline MRI, does the radiology report state evidence of any new or enlarged gadolinium-enhancing lesions?

    
 nmlkji

yes  
 nmlkji

no  

 
 

84  In comparison to the baseline MRI, does the radiology report a change in the overall burden of MS-specific lesions?

    
 nmlkji

improvement of lesion burden  

 nmlkji
worsening of lesion burden  

 nmlkji
mixed response  

 
 

85  Was the Kurtze functional systems scale conducted prior to the preparative regimen?

    (not including any FSS reported at question 48)  

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

  
 
86  Pyramidal:    

 
  

gfedcb
score unknown

  
 
87  Cerebellar:    

 
  

gfedcb
score unknown

  
 
88  Brainstem:    

 
  

gfedcb
score unknown

  
 
89  Sensory:    

 
  

gfedcb
score unknown

  
 
90  Bowel and bladder:    

 
  

gfedcb
score unknown

  
 
91  Visual:    

 
  

gfedcb
score unknown

  
 
92  Cerebral:    

 
  

gfedcb
score unknown

  
 
93  Other function:    

 
  

gfedcb
score unknown

 
 
94  Specify other function:    

  
 
95  Specify the most recent EDSS assessed prior to the preparative regimen:    

 
  

gfedcb
EDSS unknown

 
 

  
gfedcb

If the person completing this form is a Neurologist, check here and continue with the signature lines below.

  
 
First Name:    

 
Last Name:    

  
 
Phone number:    

 
Fax number:    

Form 2043 R3.0: Multiple Sclerosis Pre-HSCT data  
Center:  CRID: 

                CIBMTR Form 2043 revision 3.0 last updated July 2011
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 6



 
 
E-mail address:    

Form 2043 R3.0: Multiple Sclerosis Pre-HSCT data  
Center:  CRID: 

                CIBMTR Form 2043 revision 3.0 last updated July 2011
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 6